U.S., Canada, begin trauma experiments

May 27, 2007

The U.S. government is undertaking a set of controversial studies that allows some medical experiments without getting patients' permission.

The $50 million project aims to improve treatment after car accidents, shootings, heart attack and other emergencies, the Washington Post reported Sunday. The five-year project will involve more than 20,000 patients at 11 sites in the United States and Canada.

The experiments aim to find better ways to resuscitate people whose hearts suddenly stop, to stabilize patients in shock and to limit damage from head injuries, the Post reported.

The patients often are unconscious at a time when every minute counts, so it can be impossible to get consent from them or their families, said organizers of the studies. The project is supported by many trauma experts and some bioethicists, while the harshest critics say the experiments violate fundamental ethical principles.

The U.S. National Institutes of Health authorized the study for medical centers doing research in Seattle, Portland, San Diego, Dallas, Birmingham, Pittsburgh, Milwaukee, Toronto and Ottawa, and in Iowa and British Columbia.

Copyright 2007 by United Press International

Explore further: FDA approves new drug for rare genetic disease

add to favorites email to friend print save as pdf

Related Stories

New technologies are improving the lives of seniors

Aug 14, 2014

If Betty Lewis falls at the Edgemere senior living community, a pendant she wears around her neck will alert the staff. The device picks up the motion of the fall and notifies staff members at the North Dallas facility so ...

Designing exascale computers

Jul 23, 2014

"Imagine a heart surgeon operating to repair a blocked coronary artery. Someday soon, the surgeon might run a detailed computer simulation of blood flowing through the patient's arteries, showing how millions ...

Mental-health monitoring goes mobile

Jul 16, 2014

Behavioral health analytics startup Ginger.io sees smartphones as "automated diaries" containing valuable insight into the mental well-being of people with mental illnesses.

Recommended for you

Boxed warnings are common in novel therapeutics

21 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

23 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0